Agent Targeting BRAF Mutations Shows Promise

November 1, 2009|Dermatology

Further Trials

A phase II single arm trial (BRIM2) is evaluating 960 mg twice daily of PLX4032 in about 100 BRAF

The randomized, phase III BRIM3 trial is expected to start by the end of 2009 in first-line patients. Plexxicon is codeveloping PLX4032 with Roche.

Dr. Chapman said he had no conflicts of interest.

Melanoma is 'going to become a very exciting field instead of a graveyard.'

Source DR. EGGERMONT

Tumor shrinkage on MRI showed that, after just 15 days of treatment, FDG uptake was essentially shut down.

Source DR. CHAPMAN